A real life cohort of Mepolizumab treatment in severe eosinophilic asthma.

Laorden, D; Hernández, I; Domínguez-Ortega, J; Romero, D; Álvarez-Sala, R; Quirce, S

Laorden, D; Hernández, I; Domínguez-Ortega, J; Romero, D; Álvarez-Sala, R; Quirce, S.

Afiliação

Laorden D; Department of Pneumology, Hospital La Paz, Universidad Autónoma de Madrid, IdiPAZ, and CIBER of Respiratory Diseases, Madrid, Spain.
Hernández I; Department of Allergy, Hospital La Paz, IdiPAZ, and CIBER of Respiratory Diseases, Madrid, Spain.
Domínguez-Ortega J; Pfizer, Spain.
Romero D; Department of Allergy, Hospital La Paz, IdiPAZ, and CIBER of Respiratory Diseases, Madrid, Spain.
Álvarez-Sala R; Department of Pneumology, Hospital La Paz, Universidad Autónoma de Madrid, IdiPAZ, and CIBER of Respiratory Diseases, Madrid, Spain.
Quirce S; Department of Pneumology, Hospital La Paz, Universidad Autónoma de Madrid, IdiPAZ, and CIBER of Respiratory Diseases, Madrid, Spain.

Eur Ann Allergy Clin Immunol ; 2023 Mar 16.

Article em En | MEDLINE | ID: mdl-36927725

Palavras-chave

Asthma; anti-IL5; eosinophils; mepolizumab; oral systemic corticosteroids

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google